Lineage Cell Therapeutics Inc. Reports Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
Lineage Cell Therapeutics, Inc. (LCTX)
Company Research
Source: Yahoo! Finance
Operating Expenses : Q4 operating expenses decreased to $8.2 million, down from $8.5 million in Q4 2022. Net Loss : Q4 net loss improved to $4.8 million, or $0.03 per share, compared to a net loss of $6.4 million, or $0.03 per share, in the prior year. Cash Position : Cash, cash equivalents, and marketable securities totaled $35.5 million as of December 31, 2023. Full Year Revenue : Full year revenues were $8.9 million, a decrease from $14.7 million in the previous year. Full Year Net Loss : Full year net loss was $21.5 million, or $0.12 per share, an improvement from a net loss of $26.3 million, or $0.15 per share, in 2022. Warning! GuruFocus has detected 5 Warning Signs with LCTX. On March 7, 2024, Lineage Cell Therapeutics Inc ( LCTX ) released its 8-K filing , detailing the financial results for the fourth quarter and full year of 2023, along with a comprehensive business update. The clinical-stage biotechnology company, known for its innovative cell therapies for deg
Show less
Read more
Impact Snapshot
Event Time:
LCTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LCTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LCTX alerts
High impacting Lineage Cell Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LCTX
News
- Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate Development [Yahoo! Finance]Yahoo! Finance
- Lineage Announces Appointment of Charlotte Hubbert, Ph.D., as Vice President of Corporate DevelopmentBusiness Wire
- These 2 ‘Strong Buy' Penny Stocks Could Go Boom, Say Analysts [Yahoo! Finance]Yahoo! Finance
- Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor Symposium [Yahoo! Finance]Yahoo! Finance
- Lineage Cell Therapeutics and the Christopher & Dana Reeve Foundation Proudly Announce the 2nd Annual Spinal Cord Injury Investor SymposiumBusiness Wire
LCTX
Earnings
- 3/7/24 - Beat
LCTX
Analyst Actions
- 2/5/24 - Cantor Fitzgerald